Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Isopropamide→

Isopropamide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
7492-32-2
Molecular formula
C23H33N2O+
Molecular weight
353.5 g/mol
Drug class
Quaternary ammonium antimuscarinicgastrointestinal antispasmodic (historical)
Mechanism of action
Competitively antagonises muscarinic acetylcholine receptors in gastrointestinal smooth muscle, reducing cholinergic tone, motility and spasm. Its quaternary ammonium structure limits central nervous system penetration.
Indications / reported uses
  • Historically used for symptomatic relief of gastrointestinal hypermotility and spasm in countries where isopropamide products were authorised; availability and current indications are jurisdiction-specific

Sources: NLM MeSH — Isopropamide · PubMed — Isopropamide anticholinergic pharmacology · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Quaternary ammonium antimuscarinic; gastrointestinal antispasmodic (historical)

Mechanism of action

Competitively antagonises muscarinic acetylcholine receptors in gastrointestinal smooth muscle, reducing cholinergic tone, motility and spasm. Its quaternary ammonium structure limits central nervous system penetration.

General use cases

  • Historically used for symptomatic relief of gastrointestinal hypermotility and spasm in countries where isopropamide products were authorised; availability and current indications are jurisdiction-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Isopropamide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Isopropamide Permitted Daily Exposure (PDE) report (the Isopropamide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Isopropamide Occupational Exposure Limit (OEL) report (the Isopropamide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.